Flag of the European Union EU Clinical Trials Register Help

Clinical trials for IRES

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: IRES. Displaying page 1 of 1.
    EudraCT Number: 2019-000690-22 Sponsor Protocol Number: VAC52150EBL2002 Start Date*: 2019-04-25
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Randomized, Observer-blind, Placebo-controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Different Prime-boost Regimens of the Candidate Prophylactic Vaccines for ...
    Medical condition: Prevention of Ebola virus disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10014071 Ebola disease PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-000596-27 Sponsor Protocol Number: VAC52150EBL2001 Start Date*: 2015-05-18
    Sponsor Name:Janssen Vaccines & Prevention BV
    Full Title: A Randomized, Observer-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Safety, Tolerability and Immunogenicity of Three Prime-Boost Regimens of the Candidate Prophylactic Vaccines for Ebol...
    Medical condition: Ebola
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10014071 Ebola disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2012-004620-38 Sponsor Protocol Number: 242-12-233 Start Date*: 2019-01-14
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: Phase 2, Open-label, Multiple-dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Delamanid (OPC 67683) in Pediatric Multidrug-resistant Tuberculosis Patients on Therap...
    Medical condition: Pediatric patients with multidrug-resistant tuberculosis (MDR-TB) who are receiving an optimized background regimen (OBR) of antituberculosis drugs
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-005292-10 Sponsor Protocol Number: ERRADVIH-02 Start Date*: 2008-12-09
    Sponsor Name:Fundación para la Investigación Biomédica Hospital Ramón y Cajal
    Full Title: ESTUDIO PILOTO DEL EFECTO DE UN INHIBIDOR DE LA INTEGRASA SOBRE LA LATENCIA Y EL RESERVORIO DEL VIH-1 EN PACIENTES QUE RECIBEN TRATAMIENTO ANTIRRETROVIRAL DE GRAN ACTIVIDAD
    Medical condition: Infección por el virus de la inmunodeficiencia humana (VIH)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008919 Chronic HIV infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-008432-82 Sponsor Protocol Number: CP-MGA031-02 Start Date*: 2009-07-01
    Sponsor Name:MacroGenics, Inc.
    Full Title: A Multicenter, Multinational Extension of Study CP-MGA031-01 to Evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Chi...
    Medical condition: Recent-onset type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045228 Type I diabetes mellitus LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) ES (Prematurely Ended) SE (Prematurely Ended) LV (Prematurely Ended) EE (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-005107-26 Sponsor Protocol Number: 242-07-208 Start Date*: 2009-04-08
    Sponsor Name:Otsuka Pharmaceutical Development and Commercialization, Inc.
    Full Title: A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, tolerability, and Efficacy of Orally Administered OPC-67683 as 100 mg BID with optional titration to 200 mg BID for up t...
    Medical condition: Pulmonary Multidrug-resistant Tuberculosis (MDR TB)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037440 Pulmonary tuberculosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000691-42 Sponsor Protocol Number: VAC52150EBL3001 Start Date*: 2019-04-25
    Sponsor Name:Janssen Vaccines & Prevention B.V.
    Full Title: A Staged Phase 3 Study, Including a Double-Blinded Controlled Stage to Evaluate the Safety and Immunogenicity of Ad26.ZEBOV and MVA-BN-Filo as Candidate Prophylactic Vaccines for Ebola
    Medical condition: Prevention of Ebola virus disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10014071 Ebola disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-003995-21 Sponsor Protocol Number: ERRADVIH-01 Start Date*: 2007-12-03
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal
    Full Title: Estudio piloto del efecto de un antagonista de co-receptores CCR5 sobre la latencia y el reservorio del VIH-1 en pacientes que reciben tratamiento antirretroviral de gran actividad
    Medical condition: VIH
    Disease: Version SOC Term Classification Code Term Level
    8.1 10020192 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 08 07:28:32 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA